Loading...

BNTC BENITEC BIOPHARMA INC Expansion Plans 8-K Filing

BNTC

BNTC

BENITEC BIOPHARMA INC

(BNTC)

2025 8-K

Summary

Summary

Financial Update

Financial Statement Correct...

Product Expansion

Financial Statements

Registration Agreement

Clinical Study Results

Clinical Trial Data

Financial Results

Management Change

Management Changes

Preferred Stock Issuance

Annual Meeting Results

Financial Results

Bonus Approvals

Clinical Trial Update

Warrant Exercises

Financial Results

Stockholder Meeting

Clinical Trial Data Announc...

Appointment of Director

Earnings Reports

Private Placement

Clinical Trial Data Announc...

Grants of Executive Stock O...

Earnings Reports

Annual Meeting Approval

Earnings Reports

Departure of Directors or C...

Compliance with Nasdaq List...

Financial Results Announcement

Salary Increases

Public Offering

Stock Options Grant

Earnings Reports

Earnings Reports

External Links:

On July 9, 2025, Benitec Biopharma Inc. announced that the final subject of Cohort 1 was treated with a low dose of BB-301 in a clinical study, receiving approval to continue enrollment for the next cohort expected to begin later in 2025.

AI Assistant

BENITEC BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.